Company Overview
Snapshot
Founded in June 2017 by Miron Krokhmal, Valery Brodsky, and Vladimir Glukhman, BactoByte operates with 1-10 employees. The company has secured funding across one round from one investor, Rationalwave Capital Partners, with a Seed round in July 2019.
Business overview
BactoByte is a Health Tech & Life Sciences company focused on developing a bacterial diagnostics system. Its core technology aims to provide rapid bacterial diagnostics and antibiotic screening capabilities. The company serves the healthcare industry, specifically targeting providers such as doctors, hospitals, and clinics, to improve patient outcomes, reduce misdiagnoses, and lower healthcare costs. BactoByte operates within the Digital Healthcare and Digital Medical Diagnostics sectors, leveraging biologicals as a core technology.
Log in to access full profile ›Company Intelligence Q&A
- When was BactoByte founded and by whom?
- BactoByte was founded in June 2017 by Miron Krokhmal, Valery Brodsky, and Vladimir Glukhman.
- What is BactoByte's primary mission?
- BactoByte seeks to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capabilities to improve outcomes, reduce misdiagnoses, and lower healthcare costs.
- Which investor participated in BactoByte's Seed round?
- In July 2019, BactoByte secured Seed funding from Rationalwave Capital Partners.
- What markets does BactoByte target with its products?
- BactoByte targets geomarkets including Asia, Europe, and North America.
- What is BactoByte's current product stage?
- BactoByte's products are currently in the Research & Development (R&D) stage, focusing on developing a bacterial diagnostics system.